Tailored therapy may save colons in severe ulcerative colitis
NCT ID NCT05867329
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether personalized, adaptive treatment strategies can help people hospitalized with acute severe ulcerative colitis. The approach adjusts medication based on how each patient responds, aiming to improve outcomes and reduce the need for colon removal. The study focuses on whether these strategies are practical and acceptable to patients and doctors, paving the way for a larger trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cyclosporine (intravenous or oral)
- What this could lead to
- If successful, this could lead to a personalized treatment approach that helps more people with severe ulcerative colitis avoid removal of their colon.
- What could go wrong
- This is a feasibility pilot, so it is small and designed to test whether the approach is practical, not whether it works. Cyclosporine has side effects like kidney issues and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.